Categories: Health

Codexis Announces New Employment Inducement Grants

 | Source: Codexis, Inc.

REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company’s 2024 Inducement Plan.

The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.

Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.

About Codexis

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com

GlobeNews Wire

Recent Posts

QuisLex Releases Upcoming Event Schedule

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- New York, NY – May 7, 2025…

19 minutes ago

Ripple Price Prediction: Analysts Announce Bullish $7$10 XRP Projection for Summer StratoVM Surges 2,939% Amid Market Optimism

ROAD TOWN, British Virgin Islands, May 07, 2025 (GLOBE NEWSWIRE) -- XRP is making headlines…

19 minutes ago

FioBit, The Most Profitable Cloud Mining Platform: Passive Income Made Effortless

London, UK, May 07, 2025 (GLOBE NEWSWIRE) -- Crypto investors everywhere are feeling the tremors,…

19 minutes ago

kama.ai Launches Trustworthy Hybrid AI Agents

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- kama.ai, a leader in responsible conversational AI solutions,…

19 minutes ago

Best Same Day Loans Online No Credit Check Instant & Guaranteed Approval 2025 – Payday Ventures

HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Payday Ventures, a leading provider of online loans,…

20 minutes ago

Scenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease

In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as…

3 hours ago